{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:58:12Z","timestamp":1792835892723,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["25-A-1"],"award-info":[{"award-number":["25-A-1"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22590356"],"award-info":[{"award-number":["22590356"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23790396"],"award-info":[{"award-number":["23790396"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["S-001"],"award-info":[{"award-number":["S-001"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["10103838"],"award-info":[{"award-number":["10103838"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.lungcan.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T11:39:45Z","timestamp":1578397185000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer"],"prefix":"10.1016","volume":"141","author":[{"given":"Katsuhiro","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-4070","authenticated-orcid":false,"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akikazu","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-7119","authenticated-orcid":false,"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-3305","authenticated-orcid":false,"given":"Kazuhito","family":"Funai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shinmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0779-3088","authenticated-orcid":false,"given":"Haruhiko","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.01.005_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0020","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013Small-Cell lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0030","article-title":"Checkpoint inhibitors in metastatic EGFR-Mutated non\u2013small cell lung Cancer\u2014a meta-Analysis","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0035","first-page":"1","article-title":"IMpower150 Study Group, Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung Cancer: will expectations finally Be MET?","author":"Drilon","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0045","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/gcc.20604","article-title":"Expression and mutational analysis of MET in human solid cancers","volume":"47","author":"Ma","year":"2008","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0050","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/JTO.0000000000000685","article-title":"Clinicopathological and survival analysis of Japanese patients with resected non-small-cell lung cancer harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA gene amplification","volume":"10","author":"Inoue","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JTO.0b013e318241655f","article-title":"C-MET\/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas","volume":"7","author":"Tsuta","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in Non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-018-0185-4","article-title":"The multiple paths towards MET receptor addiction in cancer","author":"Duplaquet","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0070","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2014.32.15_suppl.8001","article-title":"Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)","volume":"32","author":"Camidge","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.108","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.064","article-title":"LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.lungcan.2018.03.016","article-title":"Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma","volume":"124","author":"Yoshimura","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0095","first-page":"160","article-title":"Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy","volume":"20","author":"Yoshimura","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0100","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0105","doi-asserted-by":"crossref","first-page":"14209","DOI":"10.18632\/oncotarget.3694","article-title":"The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2017.11.009","article-title":"Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions","volume":"115","author":"Soo","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0115","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","article-title":"Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for Cancer immunotherapy","volume":"2","author":"Zhang","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0120","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers basedon T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0130","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1158\/1078-0432.CCR-08-0133","article-title":"Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer","volume":"14","author":"Al-Shibli","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0140","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0145","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0150","doi-asserted-by":"crossref","first-page":"26845","DOI":"10.18632\/oncotarget.15839","article-title":"PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0160","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 world health organization classification of lung tumors","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0165","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.14434","article-title":"Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer","volume":"8","author":"Inoue","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-Cell lung Cancer: metlung","volume":"35","author":"Spigel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0175","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/bjc.2011.298","article-title":"MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines","volume":"105","author":"Arriola","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0180","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/gcc.22461","article-title":"Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer","volume":"56","author":"Yoshimura","year":"2017","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0185","doi-asserted-by":"crossref","DOI":"10.2353\/jmoldx.2010.090140","article-title":"Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR","author":"Brevet","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0190","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1158\/1078-0432.CCR-08-2739","article-title":"Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0195","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.humpath.2012.12.002","article-title":"Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples","volume":"44","author":"Fan","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0200","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8528","article-title":"Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer","volume":"7","author":"Inoue","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/JTO.0b013e318209edb9","article-title":"Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH","volume":"6","author":"Yi","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0210","doi-asserted-by":"crossref","DOI":"10.1097\/JTO.0000000000000157","article-title":"A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material","author":"Le Quesne","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0215","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.2013.87","article-title":"Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization","volume":"26","author":"Selinger","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0220","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0225","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0230","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/JTO.0000000000000617","article-title":"Prognostic impact of immune microenvironment in lung squamous cell carcinoma","volume":"10","author":"Kadota","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0235","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0240","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/carcin\/bgn046","article-title":"Detection of chromosome changes in pathology archives: an application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies","volume":"29","author":"Sugimura","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0245","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0250","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0255","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0260","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0265","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0270","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0280","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0285","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and Mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0290","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4494","article-title":"Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer","volume":"6","author":"Barrett","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0295","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PDL1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0300","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41416-018-0315-3","article-title":"Met inhibition revokes IFN\u03b3-induction of PD-1 ligands in MET-amplified tumours","volume":"120","author":"Martin","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science (80-.)"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0310","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0315","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/1078-0432.CCR-15-2323","article-title":"Pharmacodynamic response of the MET\/HGF Receptor to Small-Molecule tyrosine kinase inhibitors examined with validated, Fit-for-Clinic immunoassays","volume":"22","author":"Srivastava","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0320","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1349-7006.2007.00640.x","article-title":"Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines","volume":"99","author":"Nakamura","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0325","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/gcc.21950","article-title":"Opposite roles of FOXA1 and NKX2-1 in lung cancer progression","volume":"51","author":"Deutsch","year":"2012","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.lungcan.2020.01.005_bib0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","article-title":"Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma","volume":"26","author":"Parra","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.lungcan.2020.01.005_bib0335","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non\u2013small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220300052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220300052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:34:09Z","timestamp":1759235649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220300052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":67,"alternative-id":["S0169500220300052"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.01.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}